Apoptosis

The number of cells in multicellular organism is tightly regulated. Not simply by controlling the rate of cell division, but also by controlling the rate of cell death. If cells are no longer needed, they commit suicide by activating an intracellular death program. This process is therefore called programmed cell death or apoptosis (from a Greek word meaning “falling off,” as leaves from a tree). The intrinsic apoptotic pathway occurs by the release of cytochrome c from mitochondria. The extrinsic apoptotic pathway is caused by the binding of death ligands, such as TNF (tumor necrosis factor), Fas, and TRAIL (TNF-related-apoptosis-inducing ligand), to their corresponding receptors. Although programmed cell death is involved in a number of key biological phenomena, aberrant apoptosis results in diverse human diseases [1]
The amount of apoptosis that occurs in developing and adult animal tissues is surprisingly large. In the developing vertebrate nervous system up to half or more of the nerve cells normally die soon after they are formed. In a healthy adult human, billions of cells die in the bone marrow and intestine every hour. Although this process seems remarkably wasteful -especially as the vast majority are perfectly healthy at the time they kill themselves- programmed cell death plays an important role during embryonic development, as hands and feet, for example, are sculpted by apoptosis: they start out as spadelike structures, and the individual digits separate only as the cells between them die. In other cases, cells die when the structure they form is no longer needed. When a tadpole changes into a frog, the cells in the tail die, and the tail, which is not needed in the frog, disappears. In many other cases, cell death helps regulate cell numbers. In the developing nervous system, for example, cell death adjusts the number of nerve cells to match the number of target cells that require innervation. In all these cases, the cells die by apoptosis as well[2].


[2] D.R. Williams et al. An apoptosis-inducing small molecule that binds to heat shock protein 70. Angew. Chem. Int. Ed. Engl. 2008, 47, 7466-7469.
[1] B. Alberts, A. Johnson, J. Lewis et al. Molecular Biology of the Cell. 4th edition. New York. Garland Science, 2002. 

Items 1 to 30 of 54 total

per page
Page:
  1. 1
  2. 2
Axon ID Name Description From price
2469 YK 4-279 Inhibitor of ETV1, ERG and interactions of EWS-FLI1 and RNA helicase A €95.00
3801 Voruciclib Inhibitor of CDK9 Inquire
2100 Trovafloxacin mesylate Inhibitor of bacterial DNA gyrase and Topo IV €110.00
2914 TAS-103 dihydrochloride Dual inhibitor of topoisomerase I (Topo 1) and topoisomerase II (Topo 2) €95.00
3587 STM2457 First-in-class, highly potent and selective catalytic METTL3 inhibitor €130.00
1670 STF 083010 IRE1α inhibitor €95.00
2314 Stattic Nonpeptidic small-molecule inhibitor of STAT3 activation, dimerization, and nuclear translocation €50.00
2731 STAT5 Inhibitor 1 [285986-31-4] Nonpeptidic small-molecule inhibitor of STAT5 activation €90.00
2764 SIS3 Potent and selective inhibitor of Smad3 and TGF-βR1 signaling €135.00
2244 SCH 529074 Small molecule activator of mutant p53. €120.00
2313 S3I 201 Potent, cellular STAT3 inhibitor €90.00
2690 PHA-767491 Dual CDC7/CDK9 kinase inhibitor €95.00
2497 Omaveloxolone Triterpenoid activator of NRF2 and inhibitor of NF-κB €90.00
2564 NSC 59984 Activator of p53 that restores WT p53 signaling via p73 activation €95.00
1402 NSC 348884 NPM inhibitor €120.00
2016 NSC 319726 Reactivator of the p53 mutant p53R175 €95.00
2517 Napabucasin Oral first-in-class cancer stemness inhibitor that works by targeting STAT3 €105.00
3229 MYCi975 MYC inhibitor €120.00
2671 ML385 Inhibitor of NRF2 €120.00
2641 ML334 Activator of NRF2 by inhibition of Keap1-NRF2 interactions €130.00
3223 MKC8866 Potent IRE1α inhibitor €105.00
3670 MKC-3946 Potent and selective IRE1α inhibitor €120.00
2759 ME0328 PARP3/ARTD3 inhibitor €95.00
3283 LY2857785 Highly potent, selective, reversible and ATP-competitive CDK9 inhibitor €180.00
2242 Levofloxacin Q-acid Inhibitor of bacterial DNA gyrase and topoisomerase IV €55.00
3029 LDC000067 Potent, highly specific, ATP-competitive CDK9 inhibitor €110.00
1367 KU-55933 ATM inhibitor €110.00
2001 KU-0058948 hydrochloride Potent and specific PARP1 inhibitor €135.00
4179 KU-0058948 Potent and specific PARP1 inhibitor €135.00
2538 KRIBB11 HSF1 inhibitor that blocks the induction of HSP27 and HSP70 €125.00

Items 1 to 30 of 54 total

per page
Page:
  1. 1
  2. 2
Please wait...